Literature DB >> 22993466

Bilateral symmetrical corneal melting following intravesical Bacille Calmette-Guerin therapy for bladder carcinoma.

Chandana Chakraborty1, Kumaresh C Sarkar, Swati Majumdar, Krittika P Chaudhury.   

Abstract

A 63-year-old man with unremarkable previous ocular history presented with bilateral symmetrical corneal ulceration along with mucopurulent conjunctivitis and dry eye 10 days after the fourth dose of intravesical Bacille Calmette-Guerin (BCG) instillation for treatment of bladder carcinoma. Slit lamp examination revealed thinning of the cornea at the base of the ulcer in both eyes. Conjunctival swab and scraping from ulcer sent for Gram and acid fast bacilli stain and culture were negative. On the basis of history, clinical examination, and laboratory investigations, we diagnosed it as bilateral immune mediated sterile corneal ulceration along with mucopurulent conjunctivitis and dry eye. He was treated with topical antibiotics, cycloplegics, cyclosporine, lubricant gel, and bandage contact lens. There was progressive stromal melting, descemetocele formation, and perforation in the inferior part of cornea in both the eyes. He was treated with pulse steroid and paramedian tarsorraphy in both eyes. The patient was subsequently lost to follow-up. We report this case to highlight this rare complication of BCG therapy, in order to improve their management protocol in patients with similar clinical profile. We could not find a similar case after thorough PubMed search.

Entities:  

Keywords:  Bacille Calmette-Guerin; bladder carcinoma; corneal ulcer; descemetocele

Year:  2012        PMID: 22993466      PMCID: PMC3441015          DOI: 10.4103/0974-620X.99374

Source DB:  PubMed          Journal:  Oman J Ophthalmol        ISSN: 0974-620X


  10 in total

1.  Bilateral uveitis after intravesical BCG immunotherapy for bladder carcinoma.

Authors:  M Wertheim; N Astbury
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

Review 2.  Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer.

Authors:  Richard J Sylvester
Journal:  Int J Urol       Date:  2010-11-22       Impact factor: 3.369

3.  Granulomatous hepatitis, choroiditis and aortoduodenal fistula complicating intravesical Bacillus Calmette-Guérin therapy: Case report.

Authors:  Cindy Q Gao; Rozina Mithani; Jack Leya; Lesley Dawravoo; Arvin Bhatia; John Antoine; Felipe De Alba; Peter A Russo; Claus J Fimmel
Journal:  BMC Infect Dis       Date:  2011-09-30       Impact factor: 3.090

4.  Autoimmune retinopathy associated with intravesical BCG therapy.

Authors:  S Sharan; C E Thirkill; J R Grigg
Journal:  Br J Ophthalmol       Date:  2005-07       Impact factor: 4.638

5.  Reiter's syndrome during intravesical BCG therapy for bladder carcinoma.

Authors:  Maria G Tektonidou
Journal:  Clin Rheumatol       Date:  2006-08-16       Impact factor: 2.980

Review 6.  Disseminated bacille Calmette-Guérin disease after vaccination: case report and review.

Authors:  E A Talbot; M D Perkins; S F Silva; R Frothingham
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

7.  Chorioretinitis induced by intravesical Bacillus Calmette-Guérin (BCG) instillations for urinary bladder carcinoma.

Authors:  Yan Guex-Crosier; Line Chamot; Léonidas Zografos
Journal:  Klin Monbl Augenheilkd       Date:  2003-03       Impact factor: 0.700

8.  Bilateral panuveitis following intravesical BCG immunotherapy for bladder carcinoma.

Authors:  Gurmit S Uppal; Anish N Shah; Charalambos M Tossounis; Michael J Tappin
Journal:  Ocul Immunol Inflamm       Date:  2010-08       Impact factor: 3.070

9.  Mycobacterium bovis endophthalmitis from BCG immunotherapy for bladder cancer.

Authors:  S J F Gerbrandy; L C Schreuders; M D de Smet
Journal:  Ocul Immunol Inflamm       Date:  2008 May-Jun       Impact factor: 3.070

10.  Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Authors:  D L Lamm; P M van der Meijden; A Morales; S A Brosman; W J Catalona; H W Herr; M S Soloway; A Steg; F M Debruyne
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.